Alejandro Romero Martínez, PhD in Biological Sciences from the University of Vigo (2000), is a Tenured Professor in Toxicology at the University Complutense of Madrid. His research activity has resulted in 105 Journal Citation Reports (JCR) articles (h-index 38). He is also the coauthor of 12 international book chapters and 4 national. Moreover, he coauthors >50 international and >40 national congress communications and 2 patents. He has supervised two doctoral theses. He is a member of 4 editorial committees and has acted as reviewer/evaluator of 72 international journals in his specialty with JCR relative quality index. He combines his interest and background on molecular toxicology and neuroprotection studies of new molecules with therapeutic interest against neurodegeneration and focuses on novel melatonin-based therapies. He has made important contributions in cell/molecular biology of new multitarget compounds synthesized against key targets in Alzheimer’s disease and advances in the knowledge of melatonin as a pleiotropic agent against several pathologies and mechanisms of toxicity. Dr. Martinez led the MELVES project (medical countermeasures program SYP41804) to test melatonin as a potential health support measure for treatment and prophylaxis. Remarkably, the Spanish Ministry of Defence-General Directorate of Armament and Material/SDG PLATIN has displayed interest by selecting his project. He has collaborated as an external reviewer for the Czech Science Foundation and Medical Research Council’s Developmental Pathway Funding Scheme (DPFS). Moreover, he is a member of the Spanish Association of Toxicology (AETOX) since January 2011, and certified as a European Registered Toxicologist (ERT).Dr. Eva Ramos Alonso graduated in pharmacy and received her PhD in 2010 with first-class honors. She is tenured professor in Toxicology. She acquired a wide experience in alternative research to animal experimentation, with in silico techniques and in vitro tests applied to assess the safety or toxicological profile, as well as, the efficacy of a wide variety of chemical products and new molecules with therapeutic interest. Dr. Francisco López-Muñoz is PhD degree in Medicine (Complutense University of Madrid) and specialist in Pharmaceutical Medicine. Currently, he is a Full Professor of Pharmacology, Vice-Chancellor of Research and Science, Chairman of the Research Ethics Committee at Camilo José Cela University (Madrid), and a research fellow at “Hospital 12 de Octubre” Research Institute (Madrid, Spain). He is editor/author of 32 books and author of 800 scientific articles and chapters related to psychopharmacology, 197 of them with JCR impact factor (h-index 47).

• 1. Physiology and Safety of melatonin2. Translational melatonin in preclinical models3. Melatonin and COVID-194. Obtaining phytomelatonin and other bio(logical)-melatonin: sources and therapeutic applications5. Melatonin as a Therapy for Neonatal Encephalopathy: The journey to clinical trials6. Melatonin Gastroprotection by melatonin: an emerging concept and underlying mechanisms7. Melatonin as a therapeutic in the skin8. The use of melatonin in oxidative stress of the newborn9. Synergistic impact of melatonin on colorectal cancer10. Melatonin in Oncology: Unveiling its Potential in Prostate Cancer11. The use of melatonin in pediatric perioperative care12. Exploring melatonin as a therapeutic approach for mustard vesicants13. Epigenetic Modulation by Melatonin: Clinical Implications and Therapeutic Prospects14. Why Melatonin Administration might be harmful during the mounting of a defense response15. New galenic formulations of melatonin and therapeutic applications16. Melatonin, sleep and mood disorders17. Melatonin and neurodegenerative diseases18. Melatonin and autism spectrum disorders19. Melatonin and andrology20. Melatonin and hepatic injury21. Melatonin treatment against experimental optic Neuritis and glaucoma